Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr-Jun;20(2):75-82.
doi: 10.24875/AIDSRev.M18000017.

A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice

Affiliations
Review

A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice

Antonio Di Biagio et al. AIDS Rev. 2018 Apr-Jun.

Abstract

The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.

Keywords: Tefonovir alafenamide; Tefonovir disoproxil fumarate; Combination antiretroviral treatment; Atiretroviral strategies.

PubMed Disclaimer

LinkOut - more resources